JP2005506275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506275A5 JP2005506275A5 JP2002548141A JP2002548141A JP2005506275A5 JP 2005506275 A5 JP2005506275 A5 JP 2005506275A5 JP 2002548141 A JP2002548141 A JP 2002548141A JP 2002548141 A JP2002548141 A JP 2002548141A JP 2005506275 A5 JP2005506275 A5 JP 2005506275A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- fgf
- nucleotide sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25183700P | 2000-12-08 | 2000-12-08 | |
| US10/005,646 US20020151496A1 (en) | 2000-12-08 | 2001-12-07 | Novel fibroblast growth factors |
| PCT/US2001/047350 WO2002046424A2 (en) | 2000-12-08 | 2001-12-10 | Fibroblast growth factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506275A JP2005506275A (ja) | 2005-03-03 |
| JP2005506275A5 true JP2005506275A5 (enExample) | 2005-06-09 |
Family
ID=26674594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002548141A Pending JP2005506275A (ja) | 2000-12-08 | 2001-12-10 | 新規線維芽細胞増殖因子 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20020151496A1 (enExample) |
| EP (1) | EP1389237A2 (enExample) |
| JP (1) | JP2005506275A (enExample) |
| KR (1) | KR20040052442A (enExample) |
| CN (1) | CN1518597A (enExample) |
| AU (1) | AU2603402A (enExample) |
| BG (1) | BG107888A (enExample) |
| BR (1) | BR0116507A (enExample) |
| CA (1) | CA2431374A1 (enExample) |
| CZ (1) | CZ20031570A3 (enExample) |
| EE (1) | EE200300269A (enExample) |
| HU (1) | HUP0400657A1 (enExample) |
| IL (1) | IL156259A0 (enExample) |
| MX (1) | MXPA03005142A (enExample) |
| NO (1) | NO20032573L (enExample) |
| PL (1) | PL366158A1 (enExample) |
| RU (1) | RU2329058C2 (enExample) |
| SI (1) | SI21372A (enExample) |
| SK (1) | SK7012003A3 (enExample) |
| WO (1) | WO2002046424A2 (enExample) |
| ZA (1) | ZA200305236B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253266B2 (en) | 1999-07-27 | 2007-08-07 | Curagen Corporation | Polypeptides of FGF-CX |
| US6982250B2 (en) | 2000-11-06 | 2006-01-03 | Curagen Corporation | Methods of prevention and treatment of inflammatory bowel disease |
| US7189693B2 (en) | 2000-11-06 | 2007-03-13 | Curagen Corporation | Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides |
| WO2003059270A2 (en) * | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
| WO2004090112A2 (en) | 2003-04-01 | 2004-10-21 | United States Of America Department Of Veteran's Affairs | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| WO2004105787A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Kyoto | Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders |
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| MX383664B (es) | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| RS60593B1 (sr) | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN107050428B (zh) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | Fgf20药物及其对脑创伤的治疗应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
| EP1224283A2 (en) * | 1999-10-22 | 2002-07-24 | Chiron Corporation | Human and rat fgf-20 genes and gene expression products |
| PT1232264E (pt) * | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Gene fgf-21 humano e produtos da expressão do gene |
| AU2001262934A1 (en) * | 2000-06-01 | 2001-12-11 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
| JP2004502418A (ja) * | 2000-07-03 | 2004-01-29 | キュラジェン コーポレイション | 新規の線維芽細胞増殖因子およびそれをコードする核酸 |
-
2001
- 2001-12-07 US US10/005,646 patent/US20020151496A1/en not_active Abandoned
- 2001-12-10 SK SK701-2003A patent/SK7012003A3/sk unknown
- 2001-12-10 MX MXPA03005142A patent/MXPA03005142A/es not_active Application Discontinuation
- 2001-12-10 JP JP2002548141A patent/JP2005506275A/ja active Pending
- 2001-12-10 PL PL01366158A patent/PL366158A1/xx not_active Application Discontinuation
- 2001-12-10 EE EEP200300269A patent/EE200300269A/xx unknown
- 2001-12-10 RU RU2003119657/14A patent/RU2329058C2/ru not_active IP Right Cessation
- 2001-12-10 IL IL15625901A patent/IL156259A0/xx unknown
- 2001-12-10 HU HU0400657A patent/HUP0400657A1/hu unknown
- 2001-12-10 CN CNA018202993A patent/CN1518597A/zh active Pending
- 2001-12-10 CZ CZ20031570A patent/CZ20031570A3/cs unknown
- 2001-12-10 WO PCT/US2001/047350 patent/WO2002046424A2/en not_active Ceased
- 2001-12-10 KR KR10-2003-7007614A patent/KR20040052442A/ko not_active Ceased
- 2001-12-10 CA CA002431374A patent/CA2431374A1/en not_active Abandoned
- 2001-12-10 AU AU2603402A patent/AU2603402A/xx active Pending
- 2001-12-10 BR BR0116507-0A patent/BR0116507A/pt not_active IP Right Cessation
- 2001-12-10 SI SI200120066A patent/SI21372A/sl not_active IP Right Cessation
- 2001-12-10 EP EP01995460A patent/EP1389237A2/en active Pending
-
2003
- 2003-06-06 BG BG107888A patent/BG107888A/bg unknown
- 2003-06-06 NO NO20032573A patent/NO20032573L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA2003/05236A patent/ZA200305236B/en unknown
-
2007
- 2007-06-22 US US11/821,191 patent/US20080057076A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003119657A (ru) | Новые факторы роста фибробластов | |
| JP2002532432A5 (enExample) | ||
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| EA200601121A1 (ru) | Мутеины фактора роста фибробластов 21 | |
| WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
| JP2004518632A5 (enExample) | ||
| NO20051934L (no) | Sfingosin-1-fosfatreseptoragonister ved behandling av demyelinerende lidelser. | |
| JP2003500040A5 (enExample) | ||
| Yarborough Jr | Ablation of facial scars by programmed dermabrasion | |
| KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
| BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
| JP2006524034A5 (enExample) | ||
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| JP2004527551A5 (enExample) | ||
| RU2002130200A (ru) | Композиции для доставки лекарственного средства | |
| JP2002536016A5 (enExample) | ||
| RU2001132140A (ru) | Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике | |
| JP2004532032A5 (enExample) | ||
| JP2002539827A5 (enExample) | ||
| JP2003533188A5 (enExample) | ||
| ES2242858T3 (es) | Utilizacion de toxina botulinica para obtener un producto que se utiliza en patologias articulares, particularmente coxartrosis, epicondilitis y patologia de la capsula de los musculos rotadores. | |
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| CN1556711A (zh) | 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 | |
| PL1969003T3 (pl) | Zastosowanie białka czynnika neurotroficznego | |
| BR0111852A (pt) | Nova interferona para o tratamento de esclerose múltipla |